MedTrace Logo

Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD

NCT02059434 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2019-06-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and tolerability of single doses of LAS190792 administered by inhalation to patients with mild persistent asthma and moderate to severe chronic obstructive pulmonary disease (COPD) and also to assess the ability of LAS190792 to produce bronchodilation (opening of the airways).

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma

Interventions

DRUG

LAS190792 Dose 1

DRUG

LAS190792 Dose 2

DRUG

LAS190792 Dose 3

DRUG

LAS190792 Dose 4

DRUG

LAS190792 Dose 5

DRUG

LAS190792 Dose 6

DRUG

LAS190792 Dose 1 (Part 2)

DRUG

LAS190792 Dose 2 (Part 2)

DRUG

Tiotropium 18 μg

DRUG

Indacaterol 150 μg

DRUG

Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-01
Primary Completion
2014-10-06
Completion
2014-10-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02059434 on ClinicalTrials.gov